TerSera Therapeutics LLC
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$7.7M
Doctors Paid
9,663
Transactions
27,292
2024 Total
$617,592
Payment Breakdown by Category
Research$3.3M (42.8%)
Consulting$1.6M (20.4%)
Food & Beverage$581,084 (7.6%)
Travel$101,150 (1.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $3.3M | 491 | 42.8% |
| Acquisitions | $1.9M | 2 | 24.9% |
| Consulting Fee | $1.6M | 778 | 20.4% |
| Food and Beverage | $581,084 | 25,277 | 7.6% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $115,151 | 122 | 1.5% |
| Travel and Lodging | $101,150 | 412 | 1.3% |
| Space rental or facility fees (teaching hospital only) | $55,350 | 19 | 0.7% |
| Compensation for serving as faculty or as a speaker for a medical education program | $37,303 | 30 | 0.5% |
| Honoraria | $10,625 | 3 | 0.1% |
| Education | $9,593 | 158 | 0.1% |
Payments by Type
General
$4.4M
26,801 transactions
Research
$3.3M
487 transactions
Ownership
$0
4 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| A Phase 2, Multicenter, open-label, safety and efficacy study of Xermelo (telotristat ethyl) plus first-line chemotherapy in patients with locally advanced, unresectable, recurrent or metastatic biliary tract cancer | $1.4M | 0 | 338 |
| TELEHEART: Telotristat Ethyl in a Heart Biomarker Study | $519,473 | 0 | 25 |
| Prospective assessment of patients with neuroendocrine tumors and current or prior history of carcinoid syndrome or diarrhea undergoing peptide receptor radionuclide therapy with or without telotristat ethyl (NET-PACS Trial) | $441,996 | 0 | 1 |
| A Phase 2 Exploratory Study of Intravenous Quzyttir (Cetirizine HCl Injection) Versus IV Diphenhydramine in the Prevention of Hypersesitivity Infusion Reactions | $299,054 | 0 | 41 |
| Effects of Rolapitant on Nausea/vomitting in Patients with Sarcoma Receiving Multi-day Highly Emetogenic Chemotherapy with Doxorubicin and Ofosfamide Regimen | $132,413 | 0 | 2 |
| Phase II Randomized Study to Evaluate Efficacy, Patient Satisfaction, and Compliance of the Oral Combination of Rolapitant (Varubi) Plus Ondansetron v. Ondansetron Monotherapy in Malignant Glioma Patients Receiving Radiotherapy and Concomitant Temozolomide | $120,973 | 0 | 6 |
| Telotristate with Lutathera in NETs | $50,484 | 0 | 7 |
| Role of Serotonin in Colon and Liver Cancer Growth | $50,250 | 0 | 2 |
| Effects of Rolapitant on Nausea/vomitting in Patients with Sarcoma Receiving Multi-day Highly Emetogenic Chemotherapy (HEC) with Doxorubicin and Ifosfamide Regimen (AL) | $49,655 | 0 | 1 |
| Serotonin as a biomarker to chemotherapy response in cholangiocarcinoma | $42,128 | 0 | 3 |
| Phase II Randomized Study to Evaluate Efficacy, Patient Satisfaction, and Compliance of the Oral Combination of Rolapitant (Varubi) Plus Ondansetron v. Ondansetron Monotherapy in Malignant Glioma Patients Receiving Radiotherapy (RT) and Concomitant Temozolomide | $37,765 | 0 | 3 |
| Pre-clinical investigation of tryptophan hydroxylase inhibitor telotristat ethyl for the treatment of cholangiocarcinoma | $30,398 | 0 | 1 |
| Phase II Randomized Study to Evaluate Efficacy, Patient Satisfaction, and Compliance of the Oral Combination of Roliapitant (Varubi(R)) Plus Ondansetron vs. Ondanestron Monotherapy in Mallignant Glioma Patients Receiving Radiotherapy (RT) and Concomitant Temozolmide | $25,177 | 0 | 1 |
| Prospective Study of Prialt as a First Line Intrathecal Drug Therapy | $23,998 | 0 | 1 |
| A Phase II, open-label, single-arm study of INCMGA00012 and telotristat ethyl in patients with advanced neuroendocrine tumors and carcinoid syndrome | $12,500 | 0 | 1 |
| Monitoring Telotristat Ethyl Inhibition of Tryptophan hydroxylase (TPH) in Neuroendocrine Tumors Using a-[11C]methyl-L-tryptophan (AMT)-PET | $9,925 | 0 | 1 |
| Phase II trial of androgen deprivation therapy (ADT) and pembrolizumab for advanced stage androgen receptor-positive salivary gland carcinoma: Big Ten Cancer Research Consortium | $6,206 | 0 | 47 |
| Short-Term Outcomes of a High-Volume, Low-Concentration Bolus Starting Dose Technique With Ziconotide | $3,825 | 1 | 1 |
| Randomized, parallel arm, Phase II Study of Telotristat (Xermelo) in combination with Lutetium Lu 177 Dotatate (Lutathera) in Well Differentiated Neuroendocrine Tumors (NETs) | $3,558 | 0 | 1 |
| Weight Loss in Patients with Advanced Stage Pancreatic Cancer: Role of Serotonin and Effects of Telotristat Ethyl | $2,145 | 0 | 2 |
| Evaluation of Chemotherapy Effect on Serotonin Levels & Effect of Telotristat Treatment for Controlling Weight Loss in Patients with Advanced Stage Pancreatic Cancer | $1,265 | 0 | 1 |
| The Effect of Telotristat Ethyl on RABL6A and the NAD Pathway in Neuroendocrine Tumors | $24.44 | 0 | 1 |
Payments by Medical Specialty
Top Paid Doctors — Page 3
| Doctor | Specialty | Location | Total | 2022 |
|---|---|---|---|---|
| Francesco Vetri, M.d. Ph.d, M.D. PH.D | Interventional Pain Medicine | Decatur, IL | $5,312 | $0 |
| Michel Velez, Md, MD | Internal Medicine | Orlando, FL | $5,310 | $0 |
| Azka Ali, Md, MD | Internal Medicine | Cleveland, OH | $5,288 | $0 |
| Dr. Jennifer Chan, Md, MD | Internal Medicine | Boston, MA | $5,238 | $0 |
| Ms. Namrata Vijayvergia, M.d, M.D | Medical Oncology | Philadelphia, PA | $5,083 | $0 |
| Dr. Robert Bolash, M.d, M.D | Pain Medicine | Cleveland, OH | $4,896 | $0 |
| Virginia Borges, Md, MD | Medical Oncology | Aurora, CO | $4,837 | $0 |
| Dr. Lowell Hart, M.d, M.D | Medical Oncology | Fort Myers, FL | $4,431 | $0 |
| Mark Pegram, M.d, M.D | Internal Medicine | Stanford, CA | $4,408 | $0 |
| Renuka Iyer, Md, MD | Medical Oncology | Buffalo, NY | $4,365 | $0 |
| Amitabh Gulati, Md, MD | Pain Medicine | New York, NY | $4,284 | $0 |
| Jarrod Holmes, Md, MD | Hematology & Oncology | Santa Rosa, CA | $4,269 | $0 |
| Dr. Satya Das, Md, MD | Medical Oncology | Nashville, TN | $4,212 | $0 |
| Dr. Xavier Keutgen, M.d, M.D | Surgery | Chicago, IL | $4,212 | $0 |
| Dr. Tolga Suvar | Anesthesiology | Chicago, IL | $4,192 | $0 |
| Taral Patel, Md, MD | Medical Oncology | Columbus, OH | $4,009 | $0 |
| Jason Starr, Do, DO | Hematology & Oncology | Jacksonville, FL | $3,974 | $0 |
| Dr. Mohammed Jaloudi, Md, MD | Medical Oncology | Providence, RI | $3,781 | $0 |
| Dr. Joyce Steinberg, Md, MD | Hematology & Oncology | Northbrook, IL | $3,638 | $0 |
| Dr. Michael Esposito, M.d, M.D | Anesthesiology | Vero Beach, FL | $3,587 | $0 |
| Douglas Blayney, Md, MD | Internal Medicine | Stanford, CA | $3,442 | $0 |
| Matthew Goetz, M.d, M.D | Hematology & Oncology | Rochester, MN | $3,421 | $0 |
| Wynndel Buenger, Md, MD | Pain Medicine | Alton, IL | $3,402 | $0 |
| Philip Poorvu, M.d, M.D | Internal Medicine | Boston, MA | $3,385 | $0 |
| Jade Jones, M.d, M.D | Hematology & Oncology | Atlanta, GA | $3,376 | $0 |
Ad
Top Products
- Xermelo $2.8M
- Prialt $626,104
Associated Products (9)
Payment Categories
- Food & Beverage $581,084
- Consulting $1.6M
- Travel & Lodging $101,150
- Research $3.3M
About TerSera Therapeutics LLC
TerSera Therapeutics LLC has made $7.7M in payments to 9,663 healthcare providers, recorded across 27,292 transactions in the CMS Open Payments database. In 2024, the company paid $617,592. The top product by payment volume is Xermelo ($2.8M).
Payments were distributed across 163 medical specialties. The top specialty by payment amount is Urology ($1.4M to 133 doctors).
Payment categories include: Food & Beverage ($581,084), Consulting ($1.6M), Research ($3.3M), Travel & Lodging ($101,150).
TerSera Therapeutics LLC is associated with 9 products in the CMS Open Payments database, including Xermelo, Zoladex, and ZOLADEX.